Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch [Yahoo! Finance]
Alumis to Participate in Upcoming September Investor Conferences
Alumis Inc. (NASDAQ: ALMS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis [Yahoo! Finance]